Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Shi SR, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.J Histochem Cytochem 39:741–748, 1991.
Al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM, Wafflart J, Caveriviere P, Bayard F, Delson G: Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER).IntJ Cancer 55:651–654, 1993.
Goulding H, Pinder S, Cannon R, Pearson D, Nicholson R, Snead D, Bell J, Elston CW, Robertoson JF, Blarney RW,et al: A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples.Hum Pathol 26:291–294, 1995.
Zofrani B, Aubriot M-H, Mouret E, de Cremoux P, de Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelenat H, Sastre-Garau X: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases.Histopathol 37:536–545, 2000.
Snead DRJ, Bell JA, Dion AR, Nicholson RI, Elston CW, Blarney RW, Ellis IO: Methodology of immunohistochemical detection of oestorogen receptor in human breast carcinoma in in formalin-fixed paraffin-embedded tissue: a comparison with frozen section methodology.Histopathol 23:233–238, 1993.
Barnes DM, Millis RR, Beex LVAM, Thorpe SM, Leake RE: Increased use of immunohistchemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance.Eur J Cancer 34:1677–1682, 1998.
Rhodes A, Jasani B, Barnes D, Bobrow LG, Miller KD: The reliability of immunohistochemical demonstration of estrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring system.J Clin Pathol 53:125–130, 2000.
Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD: Immunohistochemical determination of oestrogen receptor: comparision of differnce methods of assessment of staining and correlation with clinical outcome of breast cancer patients.Br J Cancer 74:1445–1451, 1996.
Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD: Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.J Clin Pathol 53:688–696, 2000.
Thike AA, Chng MJ, Fook-Chong S, Tan PH: immunohistochemical expression of hormone receptor in invasive breast carcinoma: correlation of results of H-score with pathological parameters.Pathol 33:21–25, 2001.
Jensen V, Andersen J: Value of immunohistochemical-determined estrogen receptor status and proliferative activity in breast cancer: a retrospective study including patients treated by endocrine therapy at the time of recurrence.Breast 5:127–134, 1996.
Leake R: Prediction of hormone sensitivity-the receptor years and onwards.Endocrine-Related Cancer 4:289–296, 1997.
Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol 11:155–168, 1998.
Ferrero-Pous M, Trassard M, Doussal VL, Hacene K, Tubiana-Hulin M, Spyratos F: Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients.Appl Immunohistochem Molecular Morphol 9:267–275, 2001.
Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol 17:1474–1481, 1999.
Regitnig P, Reiner A, Dinges HP, Hoefler G, Muller HE, Lax SF, Obrist P, Rudas M, Quehenberger F: Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.Virchows Archiv 441:328–334, 2002.
Early Breast Cancer Trialists’ Collaboration Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women.Lancet 339:1–15, 71-85, 1992.
Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM: The effect of c-erbB2 and oestrogen receptor status on survival women with primary breast cancer treated with adjuvant CMF.Int J Cancer 84:354–359, 1999.
Barnes DM, Hanby AM: Oestrogen and progesterone receptors in breast cancer: past, present and feature.Histopathol 38:271–274, 2001.
MacGrogan G, Soubeyran G, de Mascarel I: Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: a correlative study of 942 cases.Appl Immunohistochem 4:219–227, 1996.
Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptors as a prognostic factor in stage II breast cancer.N Engl J Med 309:1343–1347, 1983.
Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N: Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.Cancer Res 47:6126–6133, 1987.